Objectives: To describe clinical characteristics of patients with Still's disease treated with methotrexate (MTX) and to assess drug effectiveness evaluating change in disease activity, reduction of inflammatory markers, and glucocorticoid (GC)-sparing effect. Methods: Patients with Still's disease treated with MTX were assessed among those included in AIDA Network Still Disease Registry.Results: In this registry, 171 patients with Still's disease were treated with MTX (males 43.3%, age 37.1 & PLUSMN; 16.0 years). They were mainly characterised by joint features and fever without a prominent multiorgan involvement. MTX was administered with GCs in 68.4% of patients, with other conventional synthetic DMARDs in 6.4%, and with biologic DMARDs in 25.1%. A significant reduction of the modified systemic score was observed, and 38.6% patients were codified as being in clinical remission at the end of follow-up. The concomitant administration of a biologic DMARD resulted a predictor of the clinical remission. Furthermore, a reduction of inflammatory markers and ferritin levels was observed following the administration of MTX. Additionally, a marked reduction of the dosage of concomitant GCs was identified, while 36.7% discontinued such drugs. Male gender appeared as a predictor of GC discontinuation. MTX was discontinued in 12.3% of patients because of adverse effects, and in 12.3% for lack of efficacy.Conclusions: Clinical characteristics of patients with Still's disease treated with MTX were described, mainly joint features and fever without a prominent multiorgan involvement. The clinical usefulness of MTX was reported in reducing the disease activity, decreasing the inflammatory markers, and as GC-sparing agent.

Ruscitti, P., Sota, J., Vitale, A., Lopalco, G., Iannone, F., Morrone, M., et al. (2023). The administration of methotrexate in patients with Still's disease, "real-life" findings from AIDA Network Still Disease Registry. SEMINARS IN ARTHRITIS AND RHEUMATISM, 62, 152244 [10.1016/j.semarthrit.2023.152244].

The administration of methotrexate in patients with Still's disease, "real-life" findings from AIDA Network Still Disease Registry

Maggio, Maria Cristina;
2023-10-01

Abstract

Objectives: To describe clinical characteristics of patients with Still's disease treated with methotrexate (MTX) and to assess drug effectiveness evaluating change in disease activity, reduction of inflammatory markers, and glucocorticoid (GC)-sparing effect. Methods: Patients with Still's disease treated with MTX were assessed among those included in AIDA Network Still Disease Registry.Results: In this registry, 171 patients with Still's disease were treated with MTX (males 43.3%, age 37.1 & PLUSMN; 16.0 years). They were mainly characterised by joint features and fever without a prominent multiorgan involvement. MTX was administered with GCs in 68.4% of patients, with other conventional synthetic DMARDs in 6.4%, and with biologic DMARDs in 25.1%. A significant reduction of the modified systemic score was observed, and 38.6% patients were codified as being in clinical remission at the end of follow-up. The concomitant administration of a biologic DMARD resulted a predictor of the clinical remission. Furthermore, a reduction of inflammatory markers and ferritin levels was observed following the administration of MTX. Additionally, a marked reduction of the dosage of concomitant GCs was identified, while 36.7% discontinued such drugs. Male gender appeared as a predictor of GC discontinuation. MTX was discontinued in 12.3% of patients because of adverse effects, and in 12.3% for lack of efficacy.Conclusions: Clinical characteristics of patients with Still's disease treated with MTX were described, mainly joint features and fever without a prominent multiorgan involvement. The clinical usefulness of MTX was reported in reducing the disease activity, decreasing the inflammatory markers, and as GC-sparing agent.
ott-2023
Settore MED/38 - Pediatria Generale E Specialistica
Ruscitti, P., Sota, J., Vitale, A., Lopalco, G., Iannone, F., Morrone, M., et al. (2023). The administration of methotrexate in patients with Still's disease, "real-life" findings from AIDA Network Still Disease Registry. SEMINARS IN ARTHRITIS AND RHEUMATISM, 62, 152244 [10.1016/j.semarthrit.2023.152244].
File in questo prodotto:
File Dimensione Formato  
Maggio_et_al_The_administration_of_methotrexate_in_patients_with_Still’s_disease_1-s2.0-S0049017223000860-main.pdf

accesso aperto

Tipologia: Versione Editoriale
Dimensione 1.29 MB
Formato Adobe PDF
1.29 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/619250
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact